All
The Centricity of Decentricity
June 27th 2022Patient recruitment, retention, diversity, & safety are all factors driving the need for radical innovation in clinical research. This need was made painfully apparent during the current COVID-19 pandemic. We can no longer ‘do the same thing and expect a different result’; it’s time to take giant steps forward. Find out how Medable, the recognized industry leaders in Decentralized Clinical trials, can partner with your organization to digitally transform your clinical protocols. Your research teams can experience benefits such as; improved patient experience, higher quality outcomes data, & savings of US$25,000,000+ for individual studies. Download the White Paper now.
Tips for Tailoring eConsent for Optimal Patient Centricity
June 27th 2022Over 70% of potential research participants live >2 hours away from a research site, & patient drop-out rates can reach 30% depending on the therapeutic area. The Solution: Medable eConsent Why? 1. Medable eConsent enables the enrollment of underrepresented, diverse populations through remote consenting. 2. Medable eConsent has proven to reduce screening timelines by 50%, & increase patient engagement by 15%+.
The Building Blocks of Decentralized Clinical Trials
June 27th 2022A recent study by Morning Consult finds that >54% of US adults would be willing to participate in a clinical trial if it had a 30-minute-or-less commute. This is quite striking, given that <4% of the 328 million people in America are actively participating in clinical research today. The solution? - An accessible, intuitive digital clinical platform that connects sponsors, sites & patients, and replaces burdensome paper forms and physical visits with electronic consents (eConsent), electronic Clinical Outcome Assessments (eCOA’s), and remote visits (TeleVisits). Find out how Medable, the recognized industry leaders in Decentralized Clinical trials, can partner with your organization to digitally transform your clinical protocols. Your research teams can experience benefits such as; improved patient experience, higher quality outcomes data, & savings of US$25,000,000+ for individual studies. Download the White Paper now to learn how.
Podcast: Aseptic Sterile Fill/Finish Support for Clinical Supplies
June 20th 2022View a short podcast with Eurofins BioPharma Product Testing to learn how Eurofins overcomes the challenges faced in sterile fill finish manufacturing in the bio/pharmaceutical industry and solutions for producing small batches of sterile GMP or GLP products for use in Toxicology Studies, as well as Phase I or Phase II clinical trials by eliminating human error and other associated risks.
From development to GMP production in 100 days
May 25th 2022Antibodies and proteins are critical reagents with wide application in in vitro diagnostic developments, companion diagnostic and biomarker assays. Depending on final application, different quality standards may apply, from research use to full GMP production. Learn more about Curia’s GMP Production of antibodies & proteins for critical assays and diagnostic applications.
The benefits of end-to-end formulation and fill-finish of biologics
May 25th 2022The clinical value of biologics for the treatment of many disease indications has been accompanied by phenomenal sales. By 2026, the global market for biologics is projected to increase to $537 billion. However, getting a promising drug candidate from formulation development to clinical phase production and commercial manufacturing can be daunting. Proper formulation development has a huge impact on whether a technology transfer to clinical phase fill-finish is successful. Learn more!
Introduction to antibody libraries for display-based antibody discovery
May 25th 2022Protein engineering has greatly benefited by the advent of in vitro display platforms, where individual or large libraries of peptides or proteins are displayed on the surface of mammalian, yeast, or bacterial cells or even bacteriophage capsids. Learn more about the main principles of phage and yeast surface display platforms & how Curia can power your antibody discovery and engineering projects.